Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Small molecule tyrosine kinase inhibitors (TKIs) are often ineffective against cancers with wild-type epidermal growth factor receptor (wt-EGFR).
• TKIs induce EGFR dimerization without altering expression levels, suggesting a role for kinase-inactivated EGFR in cancer cell survival.
• EGFR possesses kinase-independent pro-survival functions that require further investigation.

Purpose of the Study:

• To characterize TKI-induced EGFR dimerization in wt-EGFR-expressing cancer cells.
• To determine the dependency of cancer cells on kinase-inactivated EGFR for survival.
• To explore novel therapeutic strategies targeting TKI resistance in wt-EGFR cancers.

Main Methods:

• Utilized wt-EGFR-expressing cancer cell lines (A549, DU145, PC3, MDA-MB-231).
• Investigated TKI-induced EGFR dimerization status and its dependence on palmitoylation.
• Assessed the impact of inhibiting palmitoylation or downregulating EGFR on TKI-resistant cells using 2-bromopalmitate, siRNA, and EGFR-downregulating peptides.

Main Results:

• TKI-induced EGFR dimerization is dependent on palmitoylation and independent of kinase activity.
• Mutations in cysteine residues critical for palmitoylation abolished TKI-induced EGFR dimerization.
• TKI-induced EGFR dimerization persists in TKI-resistant cells; inhibiting palmitoylation or downregulating EGFR is lethal to these cells.

Conclusions:

• Kinase-inactivated EGFR is a viable therapeutic target for wt-EGFR cancers.
• Inhibiting EGFR palmitoylation or downregulating EGFR expression can overcome TKI resistance.
• Targeting EGFR palmitoylation presents a promising strategy for treating TKI-resistant cancers.